Session Overview: What are the barriers to translation of microfluidic assays as diagnostic/biomarker assays, companion diagnostics and/or clinical end points? How can we adapt a research and translational strategy such that the clinical microfluidic systems can be scalable and globally adaptable, including in low-resource settings.
